Xcytrin FDA Approval Status
FDA Approved: No
Brand name: Xcytrin
Generic name: motexafin gadolinium
Dosage form: Injection
Company: Pharmacyclics, Inc.
Treatment for: Lung Cancer Brain Metastases
Xcytrin (motexafin gadolinium) is an inhibitor of thioredoxin reductase and ribonucleotide reductase intended for the treatment of non-small cell lung cancer (NSCLC) patients with brain metastases.Pharmacyclics, Inc. announced the receipt of of a not-approvable letter from the U.S. Food and Drug Administration (FDA) in December 2007.
Development Timeline for Xcytrin
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.